141 Results Found for “gastric cancer”
At European Society for Medical Oncology (ESMO) Congress 2026, new data from VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 and POTOMAC examine perioperative treatment combinations, circulating tumor DNA (ctDNA) and bladder-preserving strategies across muscle-invasive and non-muscle-invasive bladder cancer.
What are the most important developments in lower gastrointestinal oncology from ESMO 2026? Five selected studies examine key questions across locally advanced rectal cancer and metastatic and early-stage colorectal cancer. From the potential for immunotherapy to support organ preservation in dMMR/MSI-H rectal cancer, to longer-term survival outcomes with dual checkpoint inhibition and strategies to overcome acquired resistance to targeted therapy, these findings offer insights into evolving treatment approaches and their potential implications for clinical practice.
Gastrointestinal (GI) cancers constitute a major contributor to global cancer incidence and mortality and remain among the leading causes of cancer-related death worldwide despite advances in prevention, screening and supportive care.1,2 Collectively encompassing malignancies of the esophagus, stomach, liver, biliary ...
Can advances in antibody-drug conjugate design translate into meaningful survival benefits across more tumor types and earlier treatment settings, without unacceptable toxicity? Having transformed treatment for HER2-positive breast cancer, ADCs are now taking center stage in Madrid, featuring in one-third of the Presidential Symposium late-breaking abstracts. These studies illustrate a shift from established HER2-directed approaches, toward a broader landscape of targets, payloads and clinical applications. In this article, we examine the key trials to watch and the clinical questions they aim to address.
With the European Society for Medical Oncology (ESMO) Congress 2026 fast approaching, attention is turning to Madrid, where the meeting is held from 23–27th October. Whether you are joining onsite or via the virtual platform, the three Presidential Symposia are the sessions not to miss. This year they carry 12 late-breaking abstracts (LBAs) spanning melanoma, lung, genitourinary, gastrointestinal, gynecological and rare cancers. With close to 300 scientific and educational sessions to choose from, we know the programme can feel overwhelming. So we have put together a quick guide to the headline sessions: when and where they run, who is presenting, and links to explore each one in the programme planner, so you can decide which to prioritize.
The European Society for Medical Oncology (ESMO) Congress 2026 promises a compelling program of clinical data, spanning personalized cancer vaccines, next-generation antibody–drug conjugates (ADCs) and novel approaches to targeted therapy and immunotherapy. With several studies already generating excitement following positive topline announcements, all eyes will be on the full results and their potential implications for clinical practice. Below, we highlight the 12 presidential abstracts to watch, the key findings to look out for and the questions these studies could help answer.
Several late-breaking gastrointestinal oncology studies presented at ASCO 2026 highlighted how treatment selection is continuing to evolve across colorectal, hepatobiliary, gastric, and esophageal cancers, with new data on ctDNA-guided adjuvant therapy, earlier integration of targeted agents, and intensified perioperative strategies. In this round-up, we have selected six of the most important late-breakers, and examine the latest data from CIRCULATE, BREAKWATER, EMERALD-3, Neo-CRAG, SCIENCE, and RC48-C027.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
The treatment paradigm for HER2-positive advanced gastric and GEJ adenocarcinoma has been reshaped by the integration of immune checkpoint inhibitors into trastuzumab-based chemotherapy. The phase III KEYNOTE-811 trial established the benefit of adding pembrolizumab to trastuzumab and chemotherapy, whereas the HERIZON-GEA-01 trial, presented at 2026 ASCO GI Cancers Symposium, explored a distinct strategy – enhancing HER2 blockade itself through substitution with the bispecific antibody zanidatamab, with or without PD-1 inhibition.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
At ESMO25, oesophageal cancer care made substantive headway: the MATTERHORN trial established a significant overall survival benefit with perioperative durvalumab plus FLOT, while SKYSCRAPER-07 offered a provocative signal of benefit for adjuvant atezolizumab after chemoradiation in squamous disease. In this interview with Dr Michael Gibson we unpack the data, the implications for multidisciplinary practice and the future research direction.
The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the ...
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, comprising approximately 85% of all primary liver cancers.1Â Globally, it ranks as the sixth-most common cancer and the third-leading cause of cancer-related mortality, with over 900,000 new cases and 830,000 deaths ...
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2Â Even though the adoption of both primary (HPV ...
With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.
Prof. Beate Rau, recipient of the ESSO Medal, reflects on her transformative career in surgical oncology. From early inspiration to pioneering roles in CRS and HIPEC, she shares how mentorship, perseverance, and a patient-centered philosophy have shaped her leadership—and her enduring vision for global, collaborative cancer care.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.